Augurex is a collaboration-driven, biomarker-evidence based biotechnology company. Privately held, we began our research programs in 2008 focused on the 14-3-3η protein, a novel biomarker involved in the joint damage process, with current applications in rheumatoid arthritis (RA). From this initial basic research, a portfolio of 14-3-3η-centric clinical programs emerged, that is unveiling the potential of this previously unfamiliar factor in autoimmunity, and transforming the management of RA.

Clinical studies have been conducted in over 3000 patients, published in over 50 conference proceedings and five medical articles in high-impact peer-reviewed rheumatology journals, describing the clinical applications of 14-3-3η. Available as a diagnostic test, the first of the biomarker portfolio, the 14-3-3η protein assay is Health Canada approved as an IVD offered by Dynacare and provided as a laboratory-developed test in the United States through Quest Diagnostics, LabCorp and RDL.